PMID: 7513874Mar 1, 1994Paper

Empiric therapy with beta-blockers

Pacing and Clinical Electrophysiology : PACE
A Hjalmarson


The only class of drugs with significant effects on ventricular fibrillation and sudden death in humans is that of beta-blockers. The exact mechanisms for these prophylactic effects are not known but may be related to both antiischemic or antiarrhythmic influences. It seems reasonable to suggest that one should use a beta-blocker with proven effect on total mortality and sudden cardiac death after myocardial infarction as prophylaxis. Therefore, propranolol, timolol, or metoprolol, should be instituted in order to improve prognosis when there are no contraindications. In addition to possible effects on survival one would also expect to reduce the risk for new ischemic events with angina or reinfarction. In contrast, class I antiarrhythmic agents are useful for symptomatic ventricular arrhythmias but there is no proof for any effect on ventricular fibrillation and sudden cardiac death.


Dec 1, 1992·European Heart Journal·M Burnier, H R Brunner
Feb 1, 1992·Journal of the American College of Cardiology·H CalkinsF Morady
Aug 1, 1991·Circulation·B Kennedy, M G Ziegler
Sep 1, 1991·Circulation·A Fontbonne
Aug 1, 1990·The American Journal of Cardiology·J P BoisselJ C Peyrieux
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Oct 14, 1988·JAMA : the Journal of the American Medical Association·S YusufL Friedman
Jun 1, 1985·Journal of the American College of Cardiology·J E Skinner
Mar 1, 1983·Circulation·E I CurtissL S Shapiro
Jan 1, 1981·Acta Medica Scandinavica. Supplementum·G von der LippeJ Kjekshus
Apr 2, 1981·The New England Journal of Medicine·UNKNOWN Norwegian Multicenter Study Group
Mar 26, 1982·JAMA : the Journal of the American Medical Association
Mar 1, 1993·Pacing and Clinical Electrophysiology : PACE·J SiebelsK H Kuck
Oct 1, 1994·The American Journal of Cardiology·H L KennedyS Goldstein

❮ Previous
Next ❯


Mar 1, 1997·Progress in Cardiovascular Diseases·J B SorianoD E Grobbee
Jul 25, 1997·International Journal of Cardiology·L LurjeA Hjalmarson
May 14, 2008·Progress in Cardiovascular Diseases·Aysha ArshadDan Musat
Jun 13, 2000·Cardiology Clinics·J M MillerL R Scott
Aug 30, 2011·Journal of Cardiac Failure·Giuseppe MarazziGiuseppe Rosano
Oct 1, 1994·Circulation·E J Eichhorn, A Hjalmarson

❮ Previous
Next ❯

Related Concepts

Related Feeds


Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.